No Data
No Data
Gan & Lee Pharmaceuticals.'s (SHSE:603087) Market Cap Rose CN¥2.4b Last Week; Retail Investors Who Hold 42% Profited and so Did Insiders
Key Insights Significant control over Gan & Lee Pharmaceuticals by retail investors implies that the general public has more power to influence management and governance-related decisions The top 7
Gan & Lee Pharmaceuticals Anuncia Avances En Nuevos Tratamientos Para La Diabetes Y La Obesidad
- Gan & Lee Pharmaceuticals anuncia avances importantes en nuevos tratamientos para la diabetes y la obesidad en la 84a sesión científica de la Asociación Estadounidense de Diabetes PEKÍN y BRIDG
Gan & Lee Pharmaceuticals Präsentiert Bahnbrechende Daten Zu Drei Innovativen Produkten Auf Den 84. Wissenschaftlichen Tagungen Der American Diabetes Association
In einer Phase-1b/2a-Studie wurde GZR18, ein neuartiges GLP-1-Analogon, bei chinesischen Probanden mit Adipositas/Übergewicht wöchentlich und zweiwöchentlich untersucht. In präklinischen Studien
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) announced today the presentation of three abstracts featuring their investigational...
Gan & Lee Pharmaceuticals.'s (SHSE:603087) Share Price Could Signal Some Risk
When close to half the companies in the Biotechs industry in China have price-to-sales ratios (or "P/S") below 6.8x, you may consider Gan & Lee Pharmaceuticals. (SHSE:603087) as a stock to avoid entir
Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection
Gan & Lee Pharmaceuticals (SHA:603087) secured drug registration approval for its insulin glargine injection, BAGILIN, in Mexico. The long-acting insulin analog product is injected once a day and can
No Data